High-Content Screening Comparison of 1R6F Cigarette Smoke Extract and Selected Heated Tobacco and Electronic Vapour Product Aerosol Extracts in Endothelial and Bronchial Epithelial Cell Models.

Authors

Edgar Trelles Sticken, Konstantinos Papikinos, Fiona Chapman, Roman Wieczorek, Sarah Jean Pour, Torge Evenburg, Sandra Otte, Tiandan Wu, Liam Simms, Matthew Stevenson

Published in

Journal of applied toxicology : JAT. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Cigarettes induce oxidative stress and DNA damage, processes that contribute to cardiovascular and pulmonary disease. High content screening (HCS) is an increasingly valuable tool for comparative toxicology because it enables simultaneous quantification of multiple mechanistic endpoints at single-cell resolution. In this study, HCS was used to compare the biological activity of extracts from reference cigarette 1R6F smoke and aerosol extracts from one heated tobacco product and two electronic vapour products in human coronary artery endothelial cells and bronchial epithelial cells. Endpoints included reactive oxygen species generation, glutathione depletion, γH2AX induction as a marker of DNA double-strand break signalling and NRF2 translocation as an indicator of oxidative stress signalling. 1R6F cigarette smoke extract showed the highest cytotoxic and genotoxic responses, whereas the selected HTP and EVP aerosol extracts generally showed lower potency, with higher minimum effective concentrations across several endpoints under the tested conditions. N-acetylcysteine (NAC) attenuated several responses, supporting oxidative stress as an important contributor to the observed cellular effects. Overall, under the tested in vitro conditions, extracts from the selected HTP and EVP products showed lower potency across several oxidative stress-, genotoxicity- and cytotoxicity-associated endpoints than 1R6F cigarette smoke extract. These findings support product-specific comparative in vitro bioactivity assessment but do not directly establish reduced human health risk, product safety or clinical harm reduction. The study extends previous HCS work by integrating potency-based comparisons, mechanistic interrogation using NAC and cross-tissue evaluation.

PMID:
42833661
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.